National Mammography Day: A Closer Look at Recent Studies and Breast Cancer Screening

The additional FDA 510(k) clearance for the AI-powered cmAngio platform covers use of the software for GE HealthCare mammography systems.

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

A systematic review of 147 clinical trials assessing neoadjuvant systemic therapy for breast cancer also revealed that mid-treatment imaging was utilized in 56 percent of the studies.

While standalone AI interpretation offered over 10 percent higher sensitivity than radiologists for patients undergoing post-mastectomy surveillance mammography, it missed over 30 percent of breast cancers.